Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Valerie L Teal"'
Autor:
Ajit P Limaye, Klemens Budde, Atul Humar, Julia Garcia-Diaz, Robert P Carroll, Yoshihiko Murata, Valerie L Teal, Christopher L Gilbert, Barbara A Haber
Publikováno v:
Open Forum Infectious Diseases. 9
Background VGCV is approved for prophylaxis in adult KTRs at high risk for CMV disease (donor CMV-seropositive/recipient CMV-seronegative [D+/R-]); however, its use is limited by myelosuppression. LET is non-myelotoxic, does not require dose modifica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a55e992f75a8b646b7ad5113af15f74a
https://doi.org/10.1093/ofid/ofac492.1897
https://doi.org/10.1093/ofid/ofac492.1897
Autor:
Shahrul Mt-Isa, Hong Wan, Yoav Golan, Cyrus Badshah, Sanjeet Dadwal, Valerie L Teal, Yuexin Tang
Publikováno v:
PharmacoEconomics Open
Background Allogeneic hematopoietic stem cell transplantation (HSCT) is associated with substantial healthcare resource use, particularly when recipients develop cytomegalovirus (CMV) infection. Letermovir reduced post-HSCT CMV infection risk compare
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41c844356fcc2f5b0cdf9b0d54a3454a
https://doi.org/10.1007/s41669-021-00264-9
https://doi.org/10.1007/s41669-021-00264-9
Autor:
Roy F. Chemaly, Wendy W. Yeh, Per Ljungman, Valerie L Teal, Randi Y. Leavitt, Cyrus Badshah, Hong Wan, Francisco M. Marty, Joan R. Butterton
Publikováno v:
American Journal of Transplantation. 20:1703-1711
Letermovir, a cytomegalovirus (CMV) terminase-complex inhibitor, is indicated for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of allogeneic hematopoietic cell transplantation (HCT). In a phase III, double-blind, rand
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cca12ae51a30f4471fd51f6b2f969ea7
https://doi.org/10.1111/ajt.15764
https://doi.org/10.1111/ajt.15764
Autor:
Sanjeet Singh Dadwal, Domenico Russo, Matthias Stelljes, Michael Schmitt, Sylvain Pilorge, Valerie L. Teal, Barbara A. Haber, Charlene Bopp, Cyrus Badshah
Publikováno v:
Transplantation and Cellular Therapy. 29:S64
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f55c36b71a36437b48ce493724b0442a
https://doi.org/10.1016/s2666-6367(23)00145-8
https://doi.org/10.1016/s2666-6367(23)00145-8
Publikováno v:
European Journal of Obstetrics & Gynecology and Reproductive Biology. 232:101-105
To compare the Follicular Output Rate (FORT) between corifollitropin alfa (CFA) and recombinant follicle-stimulating hormone (rFSH) during controlled ovarian stimulation (COS).This retrospective analysis compared FORT between women treated with CFA o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dd4bedb6cd32358e3a91e708d329140
https://doi.org/10.1016/j.ejogrb.2018.11.002
https://doi.org/10.1016/j.ejogrb.2018.11.002
Autor:
Cyrus Badshah, Kathleen M. Mullane, Andrew J. Ullmann, Shariq Haider, Randi Y. Leavitt, Yoshihiko Murata, Francisco M. Marty, Johan Maertens, Per Ljungman, Hong Wan, Michael Boeckh, Emily A. Blumberg, Sanjeet Dadwal, Yuta Katayama, Roy F. Chemaly, Nicholas A. Kartsonis, David R. Snydman, Hermann Einsele, Yoshinobu Kanda, Mark J. DiNubile, Rafael F. Duarte, Janice M. Brown, Valerie L Teal
Publikováno v:
New England Journal of Medicine. 377:2433-2444
BACKGROUND: Cytomegalovirus (CMV) infection remains a common complication after allogeneic hematopoietic-cell transplantation. Letermovir is an antiviral drug that inhibits the CMV-terminase complex. METHODS: In this phase 3, double-blind trial, we r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e6160b718072a6e17d3f9a0a037de8f
https://doi.org/10.1056/nejmoa1706640
https://doi.org/10.1056/nejmoa1706640
Autor:
Alexander Wong, Deborah Goldstein, Anthony Rodgers, Sushma Kumar, Peter Sklar, Valerie L Teal, Cyrus Badshah, Hedy Teppler, George J. Hanna, Anton Pozniak, Josep Mallolas, Deborah A. Hepler, Edwin DeJesus, Carey Hwang, Jean-Michel Molina, Margaret A. Johnson
Publikováno v:
Journal of Acquired Immune Deficiency Syndromes (1999)
Supplemental Digital Content is Available in the Text.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34ed3df7dfa113c9003c233585bf3771
https://pubmed.ncbi.nlm.nih.gov/31425317
https://pubmed.ncbi.nlm.nih.gov/31425317
Autor:
Cyrus Badshah, Nicholas A. Kartsonis, Hong Wan, Michael Schmitt, Johan Maertens, Francisco M. Marty, Randi Y. Leavitt, Joan R. Butterton, Valerie L Teal, Roy F. Chemaly, Per Ljungman, Yoshihiko Murata, Kendra Sarratt
Publikováno v:
Clin Infect Dis
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Background In a phase 3 trial, letermovir reduced clinically significant cytomegalovirus infections (CS-CMVi) and all-cause mortality at week 24 versus placebo in CMV-seropositive allogeneic hematopoietic cell transplantation (HCT) recipients. This p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d7fd57836fc978f0f5ae986c1e7fadb
https://pubmed.ncbi.nlm.nih.gov/31179483
https://pubmed.ncbi.nlm.nih.gov/31179483
Autor:
Roy F. Chemaly, Francisco M. Marty, Valerie L Teal, Cyrus Badshah, Wendy W. Yeh, Per Ljungman, Randi Y. Leavitt, Hong Wan, Joan R. Butterton
Publikováno v:
Open Forum Infectious Diseases
Background LET prophylaxis through HCT Week 14 was highly effective in preventing clinically significant CMV infection (CS-CMVi), had a good safety profile, and was associated with lower all-cause mortality by HCT Week 24 compared with placebo (PBO).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e76b8838849fabde836a51143466c07
http://europepmc.org/articles/PMC6252851
http://europepmc.org/articles/PMC6252851
Autor:
Randi Y. Leavitt, Roy F. Chemaly, Francisco M. Marty, Cyrus Badshah, Kendra Sarratt, Per Ljungman, Yoshihiko Murata, Hong Wan, Nicholas A. Kartsonis, Michael Schmitt, Joan R. Butterton, Johan Maertens, Valerie L Teal
Publikováno v:
Open Forum Infectious Diseases
Background In a Phase III randomized, double-blind, placebo-controlled study of CMV-seropositive HCT recipients, letermovir prophylaxis significantly reduced the incidence of clinically significant CMV infections (CS-CMVi) through 24 weeks post-HCT.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75e2583fea108e6243b52256d6882d17
https://doi.org/10.1093/ofid/ofx163.726
https://doi.org/10.1093/ofid/ofx163.726